In a recent study, Schettini and colleagues evaluated the reproducibility of HER2 IHC scoring by five pathologists specialised in breast cancer, coming from different institutions, on a hundred cases, and showed that the reproducibility was suboptimal, with 35% of discordant cases, especially in the HER2-low subgroup [20]. Here, ERBB2 is linked to breast carcinoma.